We are building a global network of leading consumer healthcare partners who are well resourced to commit significant marketing spend and expertise.
Haleon - USA
In July 2023, Futura entered into a licensing agreement with world leading consumer healthcare Company Haleon (previously GSK Consumer Healthcare) for the rights to exclusively commercialise Eroxon® in the USA. As part of the agreement, Futura received an initial upfront payment of US$ 4 million, will receive further royalty payments on all sales, and potential commercial and performance driven sales milestone payments totalling between US$ 5 million and US$ 45 million payable over the course of a number of years.
Haleon will be responsible for all investment activities related to the launch and marketing of the product in the USA, with Futura providing ongoing technical support for OTC product development and commercialisation opportunities.
Cooper Consumer Health ("Cooper") - European Economic Area, United Kingdom and Switzerland
Cooper is a leading European independent self-care organisation, and has the rights to commercialise Eroxon® throughout the European Economic Area (“EEA”), the United Kingdom and Switzerland. Under the terms of the agreement, Futura received an initial upfront payment, a markup on all sales and also undisclosed cumulative sales milestone payments. The original agreement was for an initial term of five years but was extended in January 2024 to last for five years until January 2029. Futura remains legal manufacturer and is responsible for the supply of Eroxon®, through its third-party contract manufacturers.
Labatec Pharma ("Labatec") - Gulf Co-operation Council (“GCC”) region and Middle East
Swiss-based specialty pharma company Labatec has the rights to exclusively commercialise Eroxon® in the GCC region as well as Jordan, Lebanon and Iraq. The initial licence agreement term is for eight years with the ability to extend for successive two-year terms by mutual consent.
M8 Pharmaceuticals Inc ("M8") - Central and South America
Specialty biopharmaceutical company M8 has the rights to exclusively develop and commercialise Eroxon®, in Central and South America, including Brazil and Mexico which are the two largest markets for prescription treatments for ED. The agreement is for an initial term of 15 years. In November 2023 the agreement was extended from Brazil and Mexico to the rest of the Central and South American region. M8 will be responsible for all costs related to the regulatory approval and marketing of the product. Futura will provide reasonable ongoing technical support for OTC product development and commercialisation.
Menarini Korea Limited ("Menarini Korea") - South Korea
Menarini Korea, a wholly owned subsidiary of Menarini Group, has the exclusive rights to commercialise Eroxon® in South Korea. Under the terms of the agreement, Menarini is responsible for all costs related to the regulatory approval and marketing of the product in the region, including a clinical bridging study if necessary. Futura provides reasonable technical support for product development and commercialisation and received an upfront payment. Futura will supply Eroxon® from Futura’s third party contract manufacturers.